Company Description
Viatris Inc. operates as a healthcare company worldwide.
The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| Country | United States |
| Founded | 1961 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 38,000 |
| CEO | Scott Smith |
Contact Details
Address: 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 United States | |
| Phone | 724 514 1800 |
| Website | viatris.com |
Stock Details
| Ticker Symbol | VTRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001792044 |
| CUSIP Number | 92556V106 |
| ISIN Number | US92556V1061 |
| Employer ID | 83-4364296 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian S. Roman | Chief Legal Officer |
| Theodora Mistras | Chief Financial Officer |
| Paul B. Campbell | Chief Accounting Officer, Senior Vice President and Corporate Controller |
| Ramkumar V. Rayapureddy | Chief Information Officer |
| Andrew Enrietti | Chief People Officer |
| Menassie Taddese M.B.A. | President of Emerging Markets |
| Derek Glover | Chief Quality Officer |
| Lara Ramsburg | Chief Corporate Affairs Officer |
| Dr. Jeffrey Nau MMS, Ph.D. | President of Viatris Eye Care Division |
| Philippe Martin | Chief Research & Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 25, 2024 | ARS | Filing |
| Oct 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 25, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 144 | Filing |